Page 585 - medicina-integrativa_compress

CAPÍTULO 54 MENOPAUSIA 593

31. Newton KM, et al: Use of alternative therapies for menopause 55. Simon J, et al: Differential effects of estrogen-androgen and
symptoms: Results of a population-based survey. Obstet Gynecol estrogen-only therapy on vasomotor symptoms, gonadotropin
100:18-25, 2002. secretion, and endogenous androgen bioavailability in
32. MacLennan A, Broadbent JL, Lester S, Moore V: Oral oestrogen postmenopausal women. Menopause 6:138-146, 1999.
and combined oestrogen/progestogen therapy versus placebo for 56. Penotti M, et al: Effects of androgen supplementation of hormone
hot flushes. Cochrane Database Syst Rev (4):CD002978, 2004. replacement therapy on the vascular reactivity of cerebral arteries.
33. Ockene JK, et al: Symptom experience after discontinuing use of Fertil Steril 76:235-240, 2001.
estrogen plus progestin. JAMA 294:183-193, 2005. 57. Floter A, et al: Addition of testosterone to estrogen replacement
34. Aiello EJ, et al: Effect of a yearlong, moderate-intensity exercise therapy in oophorectomized women: Effects on sexuality and
intervention on the occurrence and severity of menopause symptoms well-being. Climacteric 5:357-365, 2002.
in postmenopausal women. Menopause 11:382-388, 2004. 58. Shifren JL, et al: Transdermal testosterone treatment in women
35. Lindh-Astrand L, Nedstrand E, Wyon Y, Hammar M: Vasomotor with impaired sexual function after oophorectomy. N Engl J Med
symptoms and quality of life in previously sedentary postmenopausal 343:682-688, 2000.
women randomised to physical activity or estrogen therapy. 59. Braunstein G: Testosterone patches for the treatment of low sexual
Maturitas 48:97-105, 2004. desire in surgically menopausal women [Abstract p-70]. Menopause
36. Teoman N, Ozcan A, Acar B: The effect of exercise on physical 10:587, 2003.
fitness and quality of life in postmenopausal women. Maturitas 60. Davis S, Rees M, Ribot C, et al: Efficacy and safety of testosterone
47:71-77, 2004. patches for the treatment of low sexual desire in surgically
37. Freedman R, Woodward S, Brown B, et al: Biochemical and menopausal women (abstract). Fertil Steril 80:S76, 2003.
thermoregulatory effects of behavioral treatment for menopausal 61. Barnhart KT, et al: The effect of dehydroepiandrosterone
hot flashes. Menopause 2:211-218, 1995. supplementation to symptomatic perimenopausal women on
38. Irvin JH, et al: The effects of relaxation response training on serum endocrine profiles, lipid parameters, and health-related
menopausal symptoms. J Psychosom Obstet Gynaecol 17:202-207, quality of life. J Clin Endocrinol Metab 84:3896-3902, 1999.
1996. 62. Stomati M, et al: Endocrine, neuroendocrine and behavioral effects
39. Germaine L, Freedman RR: Behavioral treatment of menopausal of oral dehydroepiandrosterone sulfate supplementation in
hot flashes: Evaluation by objective methods. J Consult Clin Psychol postmenopausal women. Gynecol Endocrinol 13:15-25, 1999.
52:1072-1079, 1984. 63. Lam PM, et al: A randomized, placebo-controlled, crossover study
40. Rankin M: Effect of low frequency sound on menopausal symptoms. of tibolone (Livial) on menopause symptoms, psychological
J Holistic Nursing 7:34-41, 1989. well-being, and dyadic relationship of postmenopausal Chinese
41. Hunter M, O’Dea I: An evaluation of a health education women and their spouses. Menopause 11:416-422, 2004.
intervention for mid-aged women: Five year follow-up of effects 64. Meeuwsen IB, et al: The influence of tibolone on quality of life in
upon knowledge, impact of menopause and health. Patient Educ postmenopausal women. Maturitas 41:35-43, 2002.
Counseling 38: 65. Winkler UH, et al: Effects of tibolone and continuous combined
249-255, 1999. hormone replacement therapy on parameters in the clotting
42. Ganz P: Managing menopausal symptoms in breast cancer cascade: A multicenter, double-blind, randomized study.
survivors: Results of a randomized controlled trial. J Natl Fertil Steril 74:10-19, 2000.
Cancer Inst 92:1054-1064, 2000. 66. Hammar M, et al: A double-blind, randomised trial comparing
43. Maclennan AH, Broadbent JL, Lester S, Moore V: Oral oestrogen the effects of tibolone and continuous combined hormone
and combined oestrogen/progestogen therapy versus placebo for replacement therapy in postmenopausal women with menopausal
hot flashes. Cochrane Database Syst Rev 2004, CD002978. symptoms. Br J Obstet Gynaecol 105:904-911, 1998.
44. Nachtigall L, Raju U, Banerjee S: Serum estradiol profiles in 67. Huber J, et al: Effects of tibolone and continuous combined
postmenopausal women undergoing three common estrogen hormone replacement therapy on bleeding rates, quality of life
replacement therapies: Association with sex-hormone binding and tolerability in postmenopausal women. BJOG 109:886-893,
globulin, estradiol, and estrone levels. Menopause 7:243-250, 2000. 2002.
45. Nelson HD, et al: Postmenopausal hormone replacement therapy: 68. Lloyd G, et al: A randomised placebo controlled trial of the effects
Scientific review. JAMA 288:872-881, 2002. of tibolone on blood pressure and lipids in hypertensive women.
46. Wren BG, et al: Transdermal progesterone and its effect on J Hum Hypertens 14:99-104, 2000.
vasomotor symptoms, blood lipid levels, bone metabolic markers, 69. Ross LA, et al: Psychological effects of hormone replacement
moods, and quality of life for postmenopausal women. Menopause therapy: A comparison of tibolone and a sequential estrogen
10:13-18, 2003. therapy. J Psychosom Obstet Gynaecol 20:88-96, 1999.
47. Leonetti HB, Longo S, Anasti JN: Transdermal progesterone 70. Stearns V, et al: Paroxetine controlled release in the treatment of
cream for vasomotor symptoms and postmenopausal bone loss. menopausal hot flashes: A randomized controlled trial. JAMA
© Elsevier. Es una publicación MASSON. Fotocopiar sin autorización es un delito.
Obstet Gynecol 94:225-228, 1999. 289:2827-2834, 2003.
48. de Wit H, et al: Effects of acute progesterone administration in 71. Evans ML, et al: Management of postmenopausal hot flushes with
healthy postmenopausal women and normally-cycling women. venlafaxine hydrochloride: A randomized, controlled trial. Obstet
Psychoneuroendocrinology 26:697-710, 2001. Gynecol 105:161-166, 2005.
49. Morrison JC, et al: The use of medroxyprogesterone acetate for 72. Tarim E, et al: Moclobemide in the treatment of hot flashes in
relief of climacteric symptoms. Am J Obstet Gynecol 138:99-104, postmenopausal women. Adv Ther 19:258-265, 2002.
1980. 73. Wesel S, Bourguignon RP, Bosuma WB: Veralipride versus
50. Schiff I, et al: Oral medroxyprogesterone in the treatment of conjugated oestrogens: A double-blind study in the management
postmenopausal symptoms. JAMA 244:1443-1445, 1980. of menopausal hot flushes. Curr Med Res Opin 8:696-700, 1984.
51. Lobo RA, et al: Comparative effects of oral esterified estrogens 74. Melis GB, et al: Effects of the dopamine antagonist veralipride on
with and without methyltestosterone on endocrine profiles and hot flushes and luteinizing hormone secretion in postmenopausal
dimensions of sexual function in postmenopausal women with women. Obstet Gynecol 72:688-692, 1988.
hypoactive sexual desire. Fertil Steril 79:1341-1352, 2003. 75. Zichella L, et al: Effects of different dopamine agonists and
52. Hickok LR, Toomey C, Speroff L: A comparison of esterified antagonists on post-menopausal hot flushes. Maturitas 8:229-237,
estrogens with and without methyltestosterone: Effects on 1986.
endometrial histology and serum lipoproteins in postmenopausal 76. David A, et al: Veralipride: Alternative antidopaminergic treatment
women. Obstet Gynecol 82:919-924, 1993. for menopausal symptoms. Am J Obstet Gynecol 158:1107-1115,
53. Dobs AS, et al: Differential effects of oral estrogen versus oral 1988.
estrogen-androgen replacement therapy on body composition in 77. Limouzin-Lamothe MA, et al: Quality of life after the menopause:
postmenopausal women. J Clin Endocrinol Metab 87:1509-1516, 2002. Influence of hormonal replacement therapy. Am J Obstet Gynecol
54. Barrett-Connor E, et al: A two-year, double-blind comparison of 170:618-624, 1994.
estrogen-androgen and conjugated estrogens in surgically 78. Clayden JR, Bell JW, Pollard P: Menopausal flushing: Double-blind
menopausal women: Effects on bone mineral density, symptoms trial of a non-hormonal medication. Br Med J 1(905):409-412,
and lipid profiles. J Reprod Med 44:1012-1020, 1999. 1974.